V5 Ultimate
Ultimate
PricingResourcesCompany
English (original)العربيةDeutschΕλληνικάEspañolFrançaisItalianoעברית日本語한국어NederlandsPolskiPortuguêsSvenska
Talk to us Log in Start free trial
Food & Beverage
  • Bakery & Confectionery
  • Food Processing
  • Ingredients & Dry Mixes
  • Sausage & Meat Products
  • Produce Packing
  • Pet Food & Pet Supplements
  • Dairy & Chilled Foods
  • Beverages & Liquid Manufacturing
  • Infant Formula
Pharma & Life Sciences
  • Radiopharmaceuticals
  • Pharmaceutical
  • Medical Devices
  • Veterinary Pharmaceuticals
  • Blood & Tissue
  • Diagnostics & IVD Kits
  • Reference Materials & Standards
  • OTC Topical Creams & Gels
Supplements & Personal Care
  • Dietary Supplements
  • Cosmetics & Personal Care
  • Cannabis & Hemp Manufacturing
  • Fragrances & Perfumery
  • Soaps & Personal Hygiene
  • Botanical Extracts & Essential Oils
Chemicals & Materials
  • Plastics & Resins
  • Agricultural Chemicals
  • Specialty & Industrial Chemicals
  • Printing Inks, Pigments & Construction Chemicals
  • Lubricants & Metalworking Fluids
  • Coatings, Adhesives & Sealants
Other Manufacturing
  • Consumer Products
  • Electronics & Electrical Assembly
  • Textiles & Nonwoven
  • Contract Manufacturing & Co-Packing
  • Packaging & Food-Contact Materials
  • Regulated Warehousing & Distribution
Explore all industries
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Why V5? Product & Features
Why V5?Product & Features
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Explore all industries
    • Bakery & Confectionery
    • Food Processing
    • Ingredients & Dry Mixes
    • Sausage & Meat Products
    • Produce Packing
    • Pet Food & Pet Supplements
    • Dairy & Chilled Foods
    • Beverages & Liquid Manufacturing
    • Infant Formula
    • Radiopharmaceuticals
    • Pharmaceutical
    • Medical Devices
    • Veterinary Pharmaceuticals
    • Blood & Tissue
    • Diagnostics & IVD Kits
    • Reference Materials & Standards
    • OTC Topical Creams & Gels
    • Dietary Supplements
    • Cosmetics & Personal Care
    • Cannabis & Hemp Manufacturing
    • Fragrances & Perfumery
    • Soaps & Personal Hygiene
    • Botanical Extracts & Essential Oils
    • Plastics & Resins
    • Agricultural Chemicals
    • Specialty & Industrial Chemicals
    • Printing Inks, Pigments & Construction Chemicals
    • Lubricants & Metalworking Fluids
    • Coatings, Adhesives & Sealants
    • Consumer Products
    • Electronics & Electrical Assembly
    • Textiles & Nonwoven
    • Contract Manufacturing & Co-Packing
    • Packaging & Food-Contact Materials
    • Regulated Warehousing & Distribution
PricingResourcesCompany
Start free trial Log in Talk to us
HomeGlossaryExcipient
Manufacturing · The complete guide

Excipient

In short

Excipients are the 'inactive' ingredients that enable drug delivery, stability, and manufacturability—but their safety and regulatory profile are anything but passive.

1,950 words · ~9 min read
White pharmaceutical powder in a stainless steel bowl on a lab bench
White pharmaceutical powder in a stainless steel bowl on a lab bench
On this page
  1. 01Defining the Role of Excipients in Modern Manufacturing
  2. 02The Myth of Inactive Ingredients: Safety and Adverse Events
  3. 03Regulatory Framework: IPEC, USP, and Compendial Grades
  4. 04The FDA Inactive Ingredient Database (IID)
  5. 05Supplier Qualification and CoA Verification
  6. 06Novel Excipients: Challenges and Opportunities
  7. 07Inventory and Lot Handling in Manufacturing
  8. 08Managing Excipient Lifecycle with V5 Ultimate
On this page · 8 sections
  1. 1Defining the Role of Excipients in Modern Manufacturing
  2. 2The Myth of Inactive Ingredients: Safety and Adverse Events
  3. 3Regulatory Framework: IPEC, USP, and Compendial Grades
  4. 4The FDA Inactive Ingredient Database (IID)
  5. 5Supplier Qualification and CoA Verification
  6. 6Novel Excipients: Challenges and Opportunities
  7. 7Inventory and Lot Handling in Manufacturing
  8. 8Managing Excipient Lifecycle with V5 Ultimate
AI · Explain it for MY operation

How does Excipient apply to your shop floor?

Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.

Your scale

01Defining the Role of Excipients in Modern Manufacturing

In pharmaceutical and supplement manufacturing, an excipient is any component of a finished dosage form other than the active pharmaceutical ingredient (API). While often labeled as 'inactive,' excipients are essential for the transformation of a raw active substance into a stable, effective, and reproducible medicine. They act as the delivery vehicle, ensuring the API reaches the intended site of action at the correct rate while maintaining physical and chemical integrity throughout the product's shelf life.

The functional roles of excipients are diverse and specific. According to USP General Chapter <1059>, excipient performance is tied directly to the critical quality attributes (CQAs) of the drug product 1. Major categories include:

  • Fillers and Diluents: Used to increase the bulk of the dosage form, particularly when the API dose is very small (e.g., microcrystalline cellulose, lactose, mannitol).
  • Binders: Agents that ensure the granules and tablets can be formed with the required mechanical strength (e.g., povidone, hydroxypropyl methylcellulose).
  • Disintegrants: Materials that facilitate the rapid breakup of a tablet or capsule in the gastrointestinal tract to allow the API to dissolve (e.g., croscarmellose sodium, sodium starch glycolate).
  • Lubricants: Used to prevent the formulation from adhering to the manufacturing equipment, such as tablet punches and dies (e.g., magnesium stearate, stearic acid).
  • Coatings: Polymers and pigments that protect the drug from environmental degradation, mask unpleasant tastes, or control the release profile (e.g., methacrylates, ethylcellulose).
  • Glidants: Substances that improve the flow properties of powder mixtures during high-speed manufacturing (e.g., colloidal silicon dioxide).

Excipients can comprise up to 90% or more of the total volume of a drug product, making their quality and consistency just as critical as the API itself for successful manufacturing outcomes.

02The Myth of Inactive Ingredients: Safety and Adverse Events

The term 'inactive ingredient' is increasingly viewed as a misnomer in clinical pharmacology. While excipients do not intended to provide a direct pharmacological effect for the primary indication of the drug, they are not biologically inert. A significant portion of the population experiences sensitivities or adverse reactions to common excipients, which can lead to complications ranging from mild discomfort to life-threatening anaphylaxis 5.

Lactose Intolerance and Sensitivities

Lactose is one of the most widely used fillers in the pharmaceutical industry. For individuals with severe lactose intolerance, the cumulative exposure from multiple medications can potentially trigger gastrointestinal symptoms. While the amount of lactose in a single tablet is typically small (often less than 500mg), patients who are steroid-dependent or have severe enzyme deficiencies must monitor their intake 1. Manufacturers are often required to disclose the presence of lactose to support patient safety.

Sulfites and Preservatives

Sulfites (such as sodium metabisulfite) are frequently used as antioxidants in both parenteral and oral formulations to prevent API degradation. However, sulfites are known to trigger severe allergic-type reactions, particularly in asthmatic patients. The FDA has issued alerts regarding the potential for life-threatening asthmatic episodes in susceptible individuals exposed to sulfite-containing drugs 2. This necessitates clear labeling and, in some cases, the search for alternative preservation systems.

Other excipients of concern include Polyethylene Glycol (PEG), which has been linked to rare but severe hypersensitivity reactions in vaccines and injectable drugs, and certain azo dyes (like Tartrazine) that are associated with hypersensitivity in children. Modern regulatory expectations, particularly in the EU under the EMA's guidelines, require that any excipient with a 'known action or effect' be listed on the product packaging to inform healthcare providers and patients 4.

03Regulatory Framework: IPEC, USP, and Compendial Grades

The manufacture and supply of excipients are governed by a complex set of global standards that differ slightly from the rigid ICH Q7 standards applied to APIs. Because many excipients are also used in the food and cosmetic industries, the pharmaceutical industry relies on the IPEC-PQG Joint Good Manufacturing Practices Guide for Pharmaceutical Excipients to bridge the gap 1.

The 2022 version of the IPEC-PQG guide aligns excipient GMP with ISO 9001:2015 principles while adding specific controls for contamination prevention, traceability, and change control. Unlike food-grade materials, 'compendial grade' excipients (labeled as USP, NF, Ph.Eur., or JP) must meet the specific identity, purity, and quality standards defined in the official pharmacopoeial monographs. Use of non-compendial grades in drug manufacturing is generally unacceptable unless a monograph does not exist.

StandardPrimary FocusEnforcement/Usage
IPEC-PQG GMPQuality Management Systems for Excipient ManufactureVoluntary global industry standard; widely accepted by regulators.
USP-NF / Ph.Eur.Material Specifications and Test MethodsLegally enforceable standards for material quality in respective regions.
USP <1078>GMP guidelines for bulk pharmaceutical excipientsInformational chapter providing a framework for excipient QMS 2.
IPEC GDPGood Distribution PracticesEnsures quality is maintained throughout the supply chain.

Regulators expect finished-dose manufacturers to perform a formal risk assessment for each excipient. This includes assessing the risk of contamination (e.g., diethylene glycol in glycerin), the complexity of the manufacturing process, and the criticality of the excipient to the final product's performance. The EU's 'Guidelines on the formalised risk assessment for ascertaining the appropriate GMP for excipients' (2015/C 95/02) is a key reference for this activity.

04The FDA Inactive Ingredient Database (IID)

The FDA Inactive Ingredient Database (IID) is a critical resource for drug developers. It contains a list of excipients that have been used in FDA-approved drug products for specific routes of administration and dosage forms 1. When a manufacturer uses an excipient at a concentration and via a route already present in the IID, the regulatory hurdle for safety data is significantly reduced, as the excipient is considered to have a 'precedent of use.'

Key metrics in the IID include:

  • Maximum Potency: The highest amount of the inactive ingredient found in a single unit of the approved drug product 5.
  • Maximum Daily Exposure (MDE): The highest amount of the ingredient a patient would be exposed to per day based on the approved labeling of the reference product 4.
  • UNII (Unique Ingredient Identifier): The alphanumeric code that uniquely identifies the substance in the FDA's Global Substance Registration System.

If a developer wishes to use an excipient at levels exceeding the IID's maximum potency or for a new route of administration, they must provide additional safety data, often including nonclinical toxicology studies, to justify the new level of exposure 1.

05Supplier Qualification and CoA Verification

Under 21 CFR 211.84, manufacturers must ensure that each lot of components (including excipients) is tested for conformity with all appropriate written specifications before use. While manufacturers can rely on the supplier's Certificate of Analysis (CoA) for most tests, they must at a minimum perform at least one specific identity test for each component lot received.

Relying on a supplier's CoA is only permissible if the manufacturer has established the reliability of the supplier's results through initial and periodic validation. This process, known as supplier qualification, typically involves:

  1. Initial Audit: A comprehensive review of the supplier's GMP compliance and quality systems.
  2. Verification Testing: Testing multiple lots in-house to confirm the results match the supplier's CoA.
  3. Periodic Re-evaluation: Ongoing monitoring of supplier performance, including quality history and periodic re-audits.
  4. Quality Agreements: Formal contracts defining the quality responsibilities of both the supplier and the manufacturer.

A CoA is not merely a piece of paper; it is a legal certification of quality. Discrepancies between in-house testing and the CoA are significant quality events that must be investigated as potential evidence of supplier failure or material adulteration.

06Novel Excipients: Challenges and Opportunities

A 'novel excipient' is an ingredient that is being used for the first time in a drug product or by a new route of administration. Because these materials lack a precedent of use in the IID, they require extensive safety evaluation similar to a new chemical entity (NCE). This includes acute toxicity, subchronic toxicity, reproductive toxicity, and genotoxicity studies 1.

The high cost and long timelines associated with novel excipient approval have historically slowed innovation in drug delivery. However, the FDA's Novel Excipient Review Pilot Program (NERPP) was launched to allow excipient manufacturers to submit safety data for review outside of a specific drug application. This aims to encourage the development of new materials that can improve the solubility of difficult APIs or enable complex long-acting injectables.

07Inventory and Lot Handling in Manufacturing

In the warehouse and on the production floor, excipients must be handled with the same level of traceability as APIs. Every lot received is assigned a unique internal tracking number, and its status (Quarantine, Released, Rejected) must be clearly visible and controlled through a validated inventory system.

Critical aspects of excipient handling include:

  • FEFO (First Expired, First Out): Ensuring that materials with the nearest expiration or retest dates are used first to minimize waste and ensure quality.
  • Environmental Control: Many excipients are hygroscopic (like certain grades of MCC or starch) and must be stored in humidity-controlled environments to prevent changes in flow or compressibility.
  • Lot-to-Lot Variability: Even when within monograph limits, subtle differences in particle size or surface area between lots can affect tablet hardness or dissolution. Manufacturers often perform 'lot-for-lot' comparisons for critical formulations.
  • Potency Adjustments: While excipients don't have 'potency' in the same way APIs do, some formulations use a 'counter-balance' or 'QS' (quantum satis) excipient to adjust the total batch mass when the API charge is recalculated for potency or moisture.

08Managing Excipient Lifecycle with V5 Ultimate

V5 Ultimate provides a robust digital framework for managing the complexities of excipient quality and compliance. By integrating supplier management, lab testing, and production records, V5 ensures that only qualified and released materials enter the manufacturing stream.

V5 Ultimate's Material Master stores compendial specifications and IID limits directly within the item record. During receiving, the system enforces the capture of the vendor CoA and triggers the required identity tests. If a lot's results fall outside the IID-precedent or the internal specification, the system prevents the material from being staged for production. For formulations requiring potency-adjusted charges, V5's dynamic dispensing engine automatically recalculates the counter-balance excipient, ensuring total batch mass remains constant while maintaining a full Part 11-compliant audit trail of the calculation.

This level of control moves beyond 'passive' compliance to active quality assurance, protecting the manufacturer from the risks associated with manual calculations and fragmented paper records.

Frequently asked questions

Q.Can an excipient ever be considered an active ingredient?+

Yes, in certain contexts. For example, glycerin is an excipient (humectant) in many tablets but can be an active ingredient in a suppository for its laxative effect. The classification depends on the intended effect and the regulatory filing for the specific drug product 5.

Q.What is the difference between a 'retest date' and an 'expiration date' for excipients?+

An expiration date is the final date a material is expected to meet its specifications when stored as directed. A retest date is a point at which the material must be sampled and re-analyzed to confirm it still meets standards. Many excipients are stable and use retest dates, allowing for continued use if the analysis remains favorable, whereas others (like certain polymers) have fixed expiration dates.

Q.How does the FDA handle 'proprietary' excipient information?+

Excipient manufacturers often submit a Drug Master File (DMF) or Excipient Master File (EMF) to the FDA. This allows the regulator to review the confidential manufacturing process and safety data without disclosing it to the drug product manufacturer. The drug manufacturer simply provides a 'Letter of Authorization' from the excipient supplier in their application.

Q.Are excipients in food supplements regulated differently than in drugs?+

Yes. In the US, excipients in dietary supplements are governed by 21 CFR Part 111 and must be 'Generally Recognized as Safe' (GRAS) or be an approved food additive. While the GMP requirements are similar in spirit, the specific safety justifications and labeling requirements (like the Supplement Facts panel) differ from the pharmaceutical IID framework.

Primary sources

  • IPEC-PQG GMP Guide (2022)
  • FDA IID Guidance (2019)
  • USP Excipient General Chapters
  • FDA Nonclinical Safety Evaluation of Excipients (2005)
  • NHS SPS Lactose Clinical Impact
  • FDA Sulfite Safety Risks

Further reading

  • API
    The active pharmaceutical ingredient for which excipients serve as the delivery vehicle.
  • Certificate of Analysis
    The primary document used to verify excipient lot quality and compendial compliance.
  • Supplier Qualification
    The risk-based process of auditing and approving excipient manufacturers.
  • Counter-Balance Excipient
    How formulations adjust for active ingredient potency variations using fillers.
  • Critical Material Attribute
    Physical and chemical properties of excipients that impact the finished product CQAs.
  • 21 CFR Part 11
    Regulatory requirements for electronic records and signatures in excipient handling.
Software that covers Excipient
V5 Ultimate (GMP)
V5 Ultimate is a full-lifecycle GMP platform for US and international manufacturers — cGMP under 21 CFR 210/211, EU GMP Parts…

Explore this topic

Excipient sits inside this topic cluster in our glossary. Every neighbour is one click away.

Pharmaceutical GMP
25 related entries

Drug-product cGMP rules, ICH Q-series, and the regulators that enforce them.

21 CFR 21021 CFR 21121 CFR 21221 CFR 58ICH Q7ICH Q9ICH Q10ICH Q2ICH Q6GxPQP ReleaseConditional ReleaseDeviationOOSOOTCAPANCRLine ClearanceTech TransferCPVAPIUSPOEL / OEBCMO / CDMO ManagementCell & Gene Therapy Manufacturing
Talk to us about Excipient

Want to see how Excipient could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.

Start free
Back to glossary
Where this term comes up
Pharmaceutical
Inside V5
  • → Score your compliance gap — then download the validation pack.
  • → Document control — one version in force, every change signed and explained.
  • → QMS — quality records next to the work they concern.
Regulatory anchors
  • IPEC-PQG
  • USP-NF
Related terms
  • → API
  • → USP
  • → CoA
  • → 21 CFR 210
  • → 21 CFR 211
  • → 21 CFR 212
  • → 21 CFR 58
  • → ICH Q7
  • → ICH Q9
  • → ICH Q10
  • → ICH Q2
  • → ICH Q6
  • → GxP
  • → QP Release
  • → Conditional Release
  • → Deviation
  • → OOS

Next Step

Try V5 with your own records, or ask a question first. Ask V5 opens with an editable question; nothing is sent until you choose to.

Start your free trial Browse All Features

Showing the site for the United States. Local spelling, dates and prices are applied automatically; change the language at the top of the page.

V5 Ultimate
Ultimate

Warehouse, quality and manufacturing software for regulated operations.

ProductIndustriesPricingResourcesSecurity & TrustCompanyLegal Centre

© S.G. Systems, LLC